Inclusion Criteria

• General good health
• Sexually active, at risk for pregnancy, and desiring contraception
• Low-risk for HIV or STD infection
• Single sexual partner who is at low-risk for HIV or STD infection for 6 months prior to study entry
• Expect to have same sexual partner for duration of the study
• Normal cyclic menses with a usual length of 21 to 35 days
• Documented history of at least two spontaneous, normal menstrual cycles since delivery, abortion, or after discontinuing hormonal contraception/hormonal therapy
• Willing to accept a risk of pregnancy
• Willing to engage in an average of 1 to 2 acts of heterosexual vaginal intercourse per week for a period of 6 months
• Willing to be fitted with a diaphragm and use the diaphragm with test product during all acts of heterosexual vaginal intercourse for the duration of the study
• Willing to only use the test product with diaphragm as the sole method of contraception over the course of the study (with the exception of emergency contraceptive pills when indicated)
• Capable of using the product and diaphragm properly
• Willing to keep a diary to record coital information, product use information, information about the use of other vaginal products, and sign and symptom data for self and partner
• Agree not to participate in any other clinical trials during the course of the study
• Written informed consent to participate in the trial

Participant's Sexual Partner Must Not Be/Have

• Infertile
• Treated for Chlamydia trachomatis or Neisseria gonorrhoeae in the 6 months prior to study entry
• HIV infected
• More than one sexual partner in the 4 months prior to study entry
• Engaged in homosexual intercourse
• Shared injection drug needles in the 6 months prior to study entry
• Allergy or sensitivity to spermicides or products containing Nonoxynol 9 or latex

Exclusion Criteria

• Pregnant or desire to become pregnant during the course of the study
• History of infertility or conditions that may lead to infertility
• Allergy or sensitivity to spermicides or products containing Nonoxynol 9 or latex
• History of toxic shock syndrome (TSS)
• Two or more urinary tract infections (UTIs) in the 12 months prior to study entry
• Current suspected or diagnosed urinary tract infection or vaginitis
• Contraindications to pregnancy (medical condition or chronic use of medications contraindicated for pregnancy)
• Treated with antibiotics for pelvic inflammatory disease (PID) without a subsequent intrauterine pregnancy
• More than one sexual partner in the 4 months prior to study entry
• Shared injection drug needles in the 6 months prior to study entry
• HIV infected or suspected HIV infection
• Genital herpes simplex virus (HSV) infection with the first occurrence (initial episode) within 3 months prior to study entry or have clinical evidence of HSV on exam
• Sexually transmitted diseases (STDs) in the 3 months prior to study entry
• Lactating or breastfeeding
• Abnormal vaginal bleeding or spotting in the month prior to study entry
• Lower abdominal or pelvic pain in the month prior to study entry
• Abnormal finding on pelvic examination which, in the view of the study investigator, precludes participation in study
• Vaginal or cervical irritation, including vaginal or cervical epithelial disruption, ulceration, bleeding, petechiae, sloughing, or areas of obvious erythema
• Vaginal or cervical biopsy or surgery in the 3 months prior to study entry
• Vaginal or systemic antibiotics, antivirals, or antifungals in the 14 days prior to study entry
• Depo-Provera injection in the 10 months prior to study
• Vaginal or cervical abnormality that would interfere with the proper placement and retention of test product and diaphragm
• Abnormal Pap smear in the 12 months prior to study entry
• Consume (on average) greater than 2 to 3 alcoholic beverages per day
• Drug abuse (recreational, prescription, or OTC) in the 12 months prior to study entry
• Investigational drug or device use in the month prior to study entry
• Previously participated in or completed this study